Professor Rury Holman

Picture of Rury Holman Highly Cited Researcher

Position:Emeritus Director

PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240


ORCID ID0000-0002-1256-874X

Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.

Latest publications

Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study
Shishi Xu et al.
Cardiovasc Diabetol. 2022;21:182

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
Milad Nazarzadeh et al.
Lancet Diabetes Endocrinol 2022;10:645-54

Empagliflozin in acute Myocardial Infarction: the EMMY trial
Dirk von Lewinskia et al.
European Heart Journal 2022

Development and Validation of a Model to Predict Cardiovascular Death, Nonfatal Myocardial Infarction, or Nonfatal Stroke in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease
Susanna R. Stevens et al.
Cardiovasc Diabetol. 2022;21:166

Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double-blind, placebo-controlled trial
José Leal et al.
J Diabetes 2022;14:455-464

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Timothy M. E. Davis et al.
Cardiovasc Diabetol. 2022;21:116